查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1663468

生物製劑合約開發市場，按服務類型、生物製劑類型、最終用戶、國家和地區分類 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Biologics Contract Development Market, By Service Type, By Biologics Type, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年生物製劑合約開發市場規模價值為 75.0965 億美元，2025 年至 2032 年的複合年成長率為 8.94%。

生物製劑合約開發市場-市場動態

個人化醫療需求的不斷成長推動了生物製劑合約開發的成長。

個人化醫療的需求不斷成長，是生物製劑合約開發市場的重要推手。個人化醫療根據個人基因特徵客製化治療方案，提高療效並減少副作用。根據美國國立衛生研究院（NIH）的數據，到2025年全球個人化醫療市場規模預計將達到3.5兆美元。

由於生物療法對於個人化醫療至關重要，因此對專業合約開發服務的需求日益成長。遺傳疾病和癌症的發生率不斷上升，進一步刺激了對生物製劑的需求，美國國立衛生研究院估計，全球約有十分之一的人患有罕見疾病，其中許多人需要生物治療。這些因素促使生物製藥公司與合約開發組織合作，以獲得必要的專業知識並有效擴大生產規模。

生物製劑合約開發市場 - 關鍵見解

根據我們的研究分析師的分析，預測期內（2025-2032 年），全球市場預計年複合成長率約為 8.94%

根據服務類型細分，預計合約製造將在 2024 年佔據最大市場佔有率

根據生物製劑類型細分，單株抗體是 2024 年領先的生物製劑類型

從地區來看，北美是 2024 年的主要收入來源

生物製劑合約開發市場-細分分析：

全球生物製劑合約開發市場根據服務類型、生物製劑類型、最終用戶和地區進行細分。

根據服務類型，市場分為三類：合約研究、合約製造和合約測試。生物製劑合約開發市場中最主要的部分是合約製造。由於對單株抗體和疫苗等生物藥物大規模生產的需求不斷增加，該領域實現了大幅成長。合約製造組織 (CMO) 為生物製藥公司提供高效生產生物製劑同時保持法規合規性所需的專業知識、設施和設備。由於生物療法需要細胞培養和發酵等專門的過程，因此外包這些服務有助於公司降低成本並縮短上市時間。對可擴展製造解決方案的需求，特別是隨著個人化醫療和複雜疾病生物療法的興起，鞏固了這一領域的重要性。

根據生物製劑類型，市場分為四大類：單株抗體、疫苗、基因療法和重組蛋白。生物製劑合約開發市場中最主要的部分是單株抗體。這個細分市場處於領先地位，因為在治療癌症、自體免疫疾病和傳染病等各種疾病方面，對單株抗體 (mAb) 的需求不斷成長。 mAb 具有高度特異性，可提供針對性治療，與傳統藥物相比，具有更好的療效和更少的副作用。隨著生物技術的進步，許多新的 mAb 已被開發出來，並被廣泛應用於個人化醫療。因此，合約開發組織（CDO）越來越專注於提供 mAb 開發和製造服務，使得這一領域成為生物製劑合約開發市場中最突出的領域。

生物製劑合約開發市場-地理洞察

北美佔據生物製劑合約開發市場的很大佔有率，這得益於其強大的醫療保健基礎設施、強大的研究能力以及對生物療法的高需求。美國食品藥物管理局（FDA）在監管生物製劑、確保治療安全性和有效性方面發揮關鍵作用，增強了市場信心。北美擁有多家領先的生物製藥公司、學術機構和合約開發組織，是生物製劑開發的重要樞紐。美國癌症、自體免疫疾病等慢性病發生率較高，進一步加速了對生物治療的需求。此外，該地區的醫療保健政策支持個人化醫療的創新和報銷，吸引了對生物製劑的大量投資。將製造和開發服務外包給專業 CDO 的趨勢日益成長，也促進了市場的成長。隨著基因組學和生物技術的進步，北美將繼續在生物製劑開發和合約服務領域保持領先地位。

美國在生物製劑合約開發市場中佔據主導地位，得益於其先進的醫療保健體系、領先的製藥公司和尖端的研究機構。美國食品藥物管理局（FDA）提供了一個完善的監管框架，確保生物製品的安全性和有效性，並增強了市場信心。該國癌症、糖尿病和自體免疫疾病等慢性病發病率很高，這推動了對生物治療的需求。此外，美國在生物技術和製藥創新領域處於全球領先地位，在個人化醫療、基因療法和單株抗體方面投入了大量資金。將生物製劑開發和製造外包給合約開發組織（CDO）的趨勢日益成長，這使得生物製藥公司能夠降低成本並專注於創新。此外，美國政府對研究資金和監管誘因的支持進一步強化了市場格局。隨著對精準醫療的日益重視，美國生物製劑合約開發市場預計將繼續保持強勁的成長軌跡。

生物製劑合約開發市場-競爭格局：

生物製劑合約開發市場的競爭格局特徵是存在幾家專注於先進技術、法規遵循和具有成本效益的解決方案的關鍵參與者。龍沙集團、藥明康德和三星生物等公司憑藉其在生物藥物開發領域的廣泛服務（包括製程開發、製造和臨床試驗支援）引領市場。例如，龍沙集團 (Lonza Group) 提供最先進的設施和專業知識，用於大規模生物製劑生產，尤其是單株抗體生產。藥明康德以其涵蓋藥物發現、開發和製造的一體化服務而聞名，並且專注於個人化醫療。三星生物製劑結合尖端的生物製造能力，著重營運效率和法規遵循。這些公司與製藥公司和生技公司保持著密切的關係，將自己定位為生物開發領域的首選合作夥伴。他們擴大生產規模、確保品質控制和適應不斷變化的監管標準的能力繼續增強他們的競爭優勢。

最新動態：

2023 年 2 月，Lonza 在美國建立了一個專注於開發臨床試驗早期藥物的新實驗室，擴大了其業務範圍。

目錄

第 1 章：生物製劑合約開發市場概覽

  • 研究範圍
  • 市場估計年限

第 2 章：執行摘要

  • 市場片段
    • 生物製劑合約開發市場片段（按服務類型）
    • 生物製劑合約開發市場片段（按生物製劑類型）
    • 生物製劑合約開發市場片段（按最終用戶）
    • 生物製劑合約開發市場（按國家/地區）摘要
    • 生物製劑合約開發市場片段（按地區）
  • 競爭洞察

第 3 章：生物製劑合約開發關鍵市場趨勢

  • 生物製劑合約開發市場促進因素
    • 市場促進因素的影響分析
  • 生物製劑合約開發市場限制
    • 市場限制的影響分析
  • 生物製劑合約開發市場機會
  • 生物製劑合約開發市場未來趨勢

第 4 章：生物製劑合約開發產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景規劃
  • 規範架構分析

第5章：生物製劑合約開發市場：地緣政治緊張局勢升級的影響

  • 新冠肺炎疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第 6 章：生物製劑合約開發市場格局

  • 2024 年生物製劑合約開發市佔率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第 7 章：生物製劑合約開發市場 - 按服務類型

  • 概述
    • 按服務類型分類的細分市場佔有率分析
    • 合約研究
    • 合約製造
    • 合約測試

生物製劑合約開發市場 - 依生物製劑類型

  • 概述
    • 按生物製劑類型分類的細分市場佔有率分析
    • 單株抗體
    • 疫苗
    • 基因療法
    • 重組蛋白

第 8 章：生物製劑合約開發市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 製藥公司
    • 生技公司
    • 學術及研究機構

第 9 章：生物製劑合約開發市場 - 按地區分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美生物製劑合約開發主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模和預測，按服務類型
    • 北美市場規模及預測（依生物製劑類型）
    • 北美市場規模及預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲生物製劑合約開發主要製造商
    • 歐洲市場規模及預測（按國家）
    • 歐洲市場規模及預測（按服務類型）
    • 歐洲市場規模及預測（依生物製劑類型）
    • 歐洲市場規模及預測（按最終用戶）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區生物製劑合約開發主要製造商
    • 亞太地區市場規模及預測（依國家/地區分類）
    • 亞太地區市場規模及預測（依服務類型）
    • 亞太地區生物製劑市場規模及預測
    • 亞太地區市場規模及預測（依最終用戶）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲 (LATAM)
    • 概述
    • 拉丁美洲生物製劑合約開發主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（按服務類型）
    • 拉丁美洲市場規模及預測（依生物製劑類型）
    • 拉丁美洲市場規模及預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲 (MEA)
    • 概述
    • 中東和非洲生物製劑合約開發主要製造商
    • MEA 市場規模及預測（依國家/地區分類）
    • MEA 市場規模和預測（按服務類型）
    • MEA 市場規模及預測（依生物製劑類型）
    • MEA 市場規模及預測（依最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其他地區

第 10 章：主要供應商分析-生物製劑合約開發產業

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • Lonza Group
    • WuXi AppTec
    • Samsung Biologics
    • Catalent
    • Boehringer Ingelheim
    • AbbVie
    • Fujifilm Diosynth Biotechnologies
    • CordenPharma
    • Samsung Biologics
    • Patheon (Thermo Fisher Scientific)
    • Merck KGaA
    • KBI Biopharma
    • Recipharm
    • Minaris Regenerative Medicine
    • Syngene International
    • Rentschler Biopharma
    • Almac Group
    • Emergent BioSolutions

第 11 章：360 度分析師視角

第 12 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4643

REPORT HIGHLIGHT

Biologics Contract Development Market size was valued at US$ 7,509.65 Million in 2024, expanding at a CAGR of 8.94% from 2025 to 2032.

The biologics contract development market refers to the industry where companies outsource the development and manufacturing of biologic drugs to specialized service providers. Biologics are complex products derived from living organisms, including monoclonal antibodies, vaccines, and gene therapies. Contract development organizations (CDOs) offer services ranging from early-stage research, process development, and clinical trials, to large-scale manufacturing. These partnerships help biopharma companies reduce costs, improve efficiency, and access specialized expertise. As the demand for biologics grows, driven by advancements in personalized medicine and rare diseases, the biologics contract development market continues to expand, with companies focusing on regulatory compliance, innovation, and cost-effective solutions.

Biologics Contract Development Market- Market Dynamics

Rising demand for personalized medicine driving biologics contract development growth.

The rising demand for personalized medicine is a significant driver for the biologics contract development market. Personalized medicine tailors' treatments to individual genetic profiles, improving efficacy and reducing adverse effects. According to the U.S. National Institutes of Health (NIH), the global market for personalized medicine is projected to reach $3.5 trillion by 2025.

As biological therapies are central to personalized medicine, the need for specialized contract development services grows. The increasing prevalence of genetic disorders and cancer further fuels demand for biologics, with the NIH estimating that about 1 in 10 people globally are living with a rare disease, many requiring biological treatments. These factors have pushed biopharma companies to partner with contract development organizations to access the necessary expertise and scale production efficiently.

Biologics Contract Development Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.94% over the forecast period (2025-2032)

Based on Service Type segmentation, Contract Manufacturing was predicted to show maximum market share in the year 2024

Based on Biologics Type segmentation, Monoclonal Antibodies were the leading Biologics Type in 2024

Based on region, North America was the leading revenue generator in 2024

Biologics Contract Development Market- Segmentation Analysis:

The Global Biologics Contract Development Market is segmented based on Service Type, Biologics Type, End-User, and Region.

The market is divided into three categories based on Service Type: Contract Research, Contract Manufacturing, and Contract Testing. The most dominant segment in the biologics contract development market is Contract Manufacturing. This segment has seen substantial growth due to the increasing demand for large-scale production of biological drugs, including monoclonal antibodies and vaccines. Contract manufacturing organizations (CMOs) provide biopharma companies with the expertise, facilities, and equipment needed to produce biologics efficiently while maintaining regulatory compliance. As biologic therapies require specialized processes, such as cell culture and fermentation, outsourcing these services helps companies reduce costs and time-to-market. The need for scalable manufacturing solutions, particularly with the rise of personalized medicine and biological therapies for complex diseases, has solidified the importance of this segment.

The market is divided into four categories based on Biologics Type: Monoclonal Antibodies, Vaccines, Gene Therapies, and Recombinant Proteins. The most dominant segment in the biologics contract development market is Monoclonal Antibodies. This segment leads due to the growing demand for monoclonal antibodies (mAbs) in the treatment of various conditions, including cancer, autoimmune disorders, and infectious diseases. mAbs are highly specific, offering targeted therapies that provide better efficacy and fewer side effects compared to traditional drugs. With advancements in biotechnology, many new mAbs have been developed, contributing to their widespread use in personalized medicine. As a result, contract development organizations (CDOs) are increasingly focused on providing services for the development and manufacturing of mAbs, making this segment the most prominent in the biologics contract development market.

Biologics Contract Development Market- Geographical Insights

North America holds a significant share of the biologics contract development market, driven by the robust healthcare infrastructure, strong research capabilities, and the high demand for biologic therapies. The U.S. Food and Drug Administration (FDA) plays a critical role in regulating biologics, ensuring the safety and efficacy of treatments, which boosts confidence in the market. North America is home to several leading biopharma companies, academic institutions, and contract development organizations, making it a key hub for biologics development. The U.S. has a high incidence of chronic diseases, including cancer and autoimmune disorders, which further accelerates the demand for biologic treatments. Additionally, the region's healthcare policies support innovation and reimbursement for personalized medicine, attracting significant investments in biologics. The increasing trend of outsourcing manufacturing and development services to specialized CDOs also adds to the market's growth. With advancements in genomics and biotechnology, North America is positioned to continue leading in biologics development and contract services.

The United States plays a dominant role in the biologics contract development market, driven by its advanced healthcare system, leading pharmaceutical companies, and cutting-edge research institutions. The U.S. Food and Drug Administration (FDA) provides a well-established regulatory framework that ensures the safety and efficacy of biological products, fostering confidence in the market. The country has a high prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which propels the demand for biological treatments. Furthermore, the U.S. is a global leader in biotechnology and pharmaceutical innovation, with significant investments in personalized medicine, gene therapies, and monoclonal antibodies. The increasing trend of outsourcing biologic development and manufacturing to contract development organizations (CDOs) allows biopharma companies to reduce costs and focus on innovation. Moreover, the U.S. government's support for research funding and regulatory incentives further strengthens the market landscape. With a growing emphasis on precision medicine, the biologics contract development market in the U.S. is expected to continue its strong growth trajectory.

Biologics Contract Development Market- Competitive Landscape:

The competitive landscape of the biologics contract development market is marked by the presence of several key players focusing on advanced technologies, regulatory compliance, and cost-effective solutions. Companies like Lonza Group, WuXi AppTec, and Samsung Biologics lead the market with their extensive service offerings in biologic drug development, including process development, manufacturing, and clinical trial support. Lonza Group, for example, offers state-of-the-art facilities and expertise in large-scale biologics production, particularly for monoclonal antibodies. WuXi AppTec is known for its integrated services across drug discovery, development, and manufacturing, with a strong emphasis on personalized medicine. Samsung Biologics combines cutting-edge biomanufacturing capabilities with a focus on operational efficiency and regulatory adherence. These companies maintain strong relationships with pharmaceutical firms and biotechnology companies, positioning themselves as preferred partners in the biologic development space. Their ability to scale production, ensure quality control, and adapt to evolving regulatory standards continues to fuel their competitive advantage.

Recent Developments:

In February 2023, Lonza expanded its footprint in the U.S. with the establishment of a new laboratory focused on developing drugs in the early stages of clinical trials.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Lonza Group
  • WuXi AppTec
  • Samsung Biologics
  • Catalent
  • Boehringer Ingelheim
  • AbbVie
  • Fujifilm Diosynth Biotechnologies
  • CordenPharma
  • Samsung Biologics
  • Patheon (Thermo Fisher Scientific)
  • Merck KGaA
  • KBI Biopharma
  • Recipharm
  • Minaris Regenerative Medicine
  • Syngene International
  • Rentschler Biopharma
  • Almac Group
  • Emergent BioSolutions

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Contract Research
  • Contract Manufacturing
  • Contract Testing

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY BIOLOGICS TYPE- MARKET ANALYSIS, 2019 - 2032

  • Monoclonal Antibodies
  • Vaccines
  • Gene Therapies
  • Recombinant Proteins

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Academic & Research Institutions

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Biologics Contract Development Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Biologics Contract Development Market Snippet by Service Type
    • 2.1.2. Biologics Contract Development Market Snippet by Biologics Type
    • 2.1.3. Biologics Contract Development Market Snippet by End-User
    • 2.1.4. Biologics Contract Development Market Snippet by Country
    • 2.1.5. Biologics Contract Development Market Snippet by Region
  • 2.2. Competitive Insights

3. Biologics Contract Development Key Market Trends

  • 3.1. Biologics Contract Development Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Biologics Contract Development Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Biologics Contract Development Market Opportunities
  • 3.4. Biologics Contract Development Market Future Trends

4. Biologics Contract Development Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Biologics Contract Development Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Biologics Contract Development Market Landscape

  • 6.1. Biologics Contract Development Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Biologics Contract Development Market - By Service Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Service Type, 2024 & 2032 (%)
    • 7.1.2. Contract Research
    • 7.1.3. Contract Manufacturing
    • 7.1.4. Contract Testing

Biologics Contract Development Market - By Biologics Type

  • 7.2. Overview
    • 7.2.1. Segment Share Analysis, By Biologics Type, 2024 & 2032 (%)
    • 7.2.2. Monoclonal Antibodies
    • 7.2.3. Vaccines
    • 7.2.4. Gene Therapies
    • 7.2.5. Recombinant Proteins

8. Biologics Contract Development Market - By End-User

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
    • 8.1.2. Pharmaceutical Companies
    • 8.1.3. Biotechnology Companies
    • 8.1.4. Academic & Research Institutions

9. Biologics Contract Development Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Biologics Contract Development Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.2.7. The U.S.
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.2.7.4. U.S. Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.2.8. Canada
      • 9.2.8.1. Overview
      • 9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.8.3. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.2.8.4. Canada Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Biologics Contract Development Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.7. Germany
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.7.4. Germany Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.8. UK
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. UK Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.8.4. UK Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.8.5. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.9.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.10. Italy
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.3. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.10.4. Italy Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.10.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.11. Spain
      • 9.3.11.1. Overview
      • 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.3. Spain Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.11.4. Spain Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.11.5. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.12. The Netherlands
      • 9.3.12.1. Overview
      • 9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.3. The Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.12.4. The Netherlands Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.12.5. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.13. Sweden
      • 9.3.13.1. Overview
      • 9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.3. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.13.4. Sweden Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.13.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.14. Russia
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Russia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.14.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.15. Poland
      • 9.3.15.1. Overview
      • 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.15.3. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.15.4. Poland Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.16. Rest of Europe
      • 9.3.16.1. Overview
      • 9.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.16.3. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.16.4. Rest of the Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.16.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Biologics Contract Development Key Manufacturers in Asia Pacific
    • 9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.4.5. APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.4.6. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.7.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.8. India
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.8.4. India Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.8.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.9. Japan
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.9.4. Japan Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.10. South Korea
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.10.4. South Korea Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.11. Australia
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Australia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.12.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.13. Thailand
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Thailand Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.13.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.14. Philippines
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Philippines Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.15. Rest of APAC
      • 9.4.15.1. Overview
      • 9.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.15.3. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.15.4. Rest of APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.5. Latin America (LATAM)
    • 9.5.1. Overview
    • 9.5.2. Biologics Contract Development Key Manufacturers in Latin America
    • 9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.5.5. LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.5.6. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.7. Brazil
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Brazil Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.8. Mexico
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Mexico Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.9. Argentina
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Argentina Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.10. Colombia
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Colombia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.11. Rest of LATAM
      • 9.5.11.1. Overview
      • 9.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.11.3. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.11.4. Rest of LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa (MEA)
    • 9.6.1. Overview
    • 9.6.2. Biologics Contract Development Key Manufacturers in the Middle East and Africa
    • 9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.6.5. MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.6.6. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.7. Saudi Arabia
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.7.4. Saudi Arabia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.8. UAE
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. UAE Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.8.4. UAE Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.8.5. UAE Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.9. Israel
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Israel Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.10. Turkey
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Turkey Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.11. Algeria
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Algeria Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.12. Egypt
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Egypt Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.13. Rest of MEA
      • 9.6.13.1. Overview
      • 9.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.13.3. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.13.4. Rest of MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Biologics Contract Development Industry

  • 10.1. Competitive Dashboard
    • 10.1.1. Competitive Benchmarking
    • 10.1.2. Competitive Positioning
  • 10.2. Company Profiles
    • 10.2.1. Lonza Group
    • 10.2.2. WuXi AppTec
    • 10.2.3. Samsung Biologics
    • 10.2.4. Catalent
    • 10.2.5. Boehringer Ingelheim
    • 10.2.6. AbbVie
    • 10.2.7. Fujifilm Diosynth Biotechnologies
    • 10.2.8. CordenPharma
    • 10.2.9. Samsung Biologics
    • 10.2.10. Patheon (Thermo Fisher Scientific)
    • 10.2.11. Merck KGaA
    • 10.2.12. KBI Biopharma
    • 10.2.13. Recipharm
    • 10.2.14. Minaris Regenerative Medicine
    • 10.2.15. Syngene International
    • 10.2.16. Rentschler Biopharma
    • 10.2.17. Almac Group
    • 10.2.18. Emergent BioSolutions

11. 360 Degree AnalystView

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us